A Phase 1, Open-label, Randomized, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 02 Aug 2024 Planned End Date changed from 21 Aug 2024 to 22 Aug 2024.
- 02 Aug 2024 Planned primary completion date changed from 21 Aug 2024 to 22 Aug 2024.